Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally, and the propagation of vegetables and ornamental plants in North America. Its segments include Canadian Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. It also has a controlling interest in Bevo Farms Ltd., North America's supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, TerraFarma Inc., Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.


TSX:ACB - Post by User

Bullboard Posts
Post by RichyRich$on Sep 23, 2020 12:08am
188 Views
Post# 31602225

The Write-Downs Were Already Known Before Q4 Report

The Write-Downs Were Already Known Before Q4 ReportRemember they reported the expected write-down for this quarter on Sep. 8. The $3.3B is just adding the write-downs from the previous quarter reports of the fiscal year. The drop in share price already reflected it. While the EBITDA improved by 25% over last quarter, and that trend shows it's true they will be EBITDA positive in early 2021. Mores Cannabis stores are popping up and overseas global sales will increase. The Price to Book P/B is still only .48 even after this fiscal year $3.3B write-down. Aphria is at P/B of .85. And Aphria most likely needs to do a write-down. Aurora is more attractive than Aphria based on the P/B ratio.
Bullboard Posts